Modification of D-galactosamine-induced liver injury in the rat by spironolactone.
Spironolactone, a competitive inhibitor of mineralocorticoid effects on the distal tubule of the kidney, has recently been found to have other metabolic effects. In these studies, spironolactone (200mg/kg intraperitoneally) for 3 days was found to have a marked protective effect against the hepatotoxic effect of D-galactosamine (275 mg/kg) in rats. Further progress in defining the mechanism of protection from D-galactosamine hepatic necrosis by spironolactone will require assessment of effects of spironolactone on uridine nucleotide metabolism.
D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001647:Bile Acids and Salts / Q000097:blood; D005688:Galactosamine / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D009336:Necrosis / Q000139:chemically induced; D051381:Rats; D013148:Spironolactone / Q000008:administration & dosage / Q000494:pharmacology*
D001647:Bile Acids and Salts; D013148:Spironolactone; D005688:Galactosamine; D001219:Aspartate Aminotransferases